Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million - Following pre-NDA meeting with FDA, on track to submit TransCon CNP ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Ascendis Pharma AS (ASND) reports significant milestones and market traction, despite facing revenue and reimbursement hurdles.

Q4 2024 Earnings Call Transcript February 12, 2025 Ascendis Pharma A/S beats earnings expectations. Reported EPS is $-0.68699 ...

CEO Jan Mikkelsen highlighted 2024 as a pivotal year, with SKYTROFA achieving €200 million in revenue and a 6.5% share of the U.S. growth hormone market. The product now holds 45% of the U.S.

We recently compiled a list of the 12 Best International Dividend Stocks To Buy Now. In this article, we are going to take a ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Novo Nordisk shares rose 4.5% after a strong Q4 profit beat, driven by high demand for obesity drug Wegovy, despite forecasting slower sales growth for 2025.

Investing.com -- Novo Nordisk 's (CSE: NOVOb ) stock jumped over 3% on Wednesday following a stronger-than-expected ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...